{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=2&sponsor=Daiichi+Sankyo+Co.%2C+Ltd.", "query": { "sponsor": "Daiichi Sankyo Co., Ltd.", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 27, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=3&sponsor=Daiichi+Sankyo+Co.%2C+Ltd.&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=1&sponsor=Daiichi+Sankyo+Co.%2C+Ltd.&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T18:22:38.058Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03529110", "title": "DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Trastuzumab deruxtecan (T-DXd)", "type": "DRUG" }, { "name": "Ado-trastuzumab emtansine (T-DM1)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 524, "start_date": "2018-08-09", "completion_date": "2026-08-31", "has_results": true, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-09T18:22:38.058Z", "location_count": 28, "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 22 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03529110" }, { "nct_id": "NCT00910299", "title": "Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Coronary Artery Disease (CAD)" ], "interventions": [ { "name": "Prasugrel", "type": "DRUG" }, { "name": "Clopidogrel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 423, "start_date": "2009-07", "completion_date": "2011-04", "has_results": true, "last_update_posted_date": "2012-06-08", "last_synced_at": "2026-10-09T18:22:38.058Z", "location_count": 9, "location_summary": "Clearwater, Florida • Jacksonville, Florida • Rome, Georgia + 6 more", "locations": [ { "city": "Clearwater", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rome", "state": "Georgia" }, { "city": "Moline", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00910299" }, { "nct_id": "NCT04619004", "title": "HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer Metastatic", "Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor" ], "interventions": [ { "name": "Patritumab Deruxtecan (Fixed dose)", "type": "DRUG" }, { "name": "Patritumab Deruxtecan (Up-Titration)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 277, "start_date": "2021-02-02", "completion_date": "2027-01-04", "has_results": true, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-10-09T18:22:38.058Z", "location_count": 33, "location_summary": "Gilbert, Arizona • Duarte, California • La Jolla, California + 27 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04619004" }, { "nct_id": "NCT04482309", "title": "A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer", "Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer" ], "interventions": [ { "name": "Trastuzumab deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 477, "start_date": "2020-08-18", "completion_date": "2027-03-23", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-10-09T18:22:38.058Z", "location_count": 12, "location_summary": "Duarte, California • Santa Rosa, California • Chicago, Illinois + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Muncie", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04482309" }, { "nct_id": "NCT03248492", "title": "A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "DS-8201a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 253, "start_date": "2017-08-25", "completion_date": "2024-05-06", "has_results": true, "last_update_posted_date": "2025-06-26", "last_synced_at": "2026-10-09T18:22:38.058Z", "location_count": 36, "location_summary": "Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 26 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03248492" }, { "nct_id": "NCT03523585", "title": "DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Lapatinib", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 608, "start_date": "2018-08-01", "completion_date": "2025-12-23", "has_results": true, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-10-09T18:22:38.058Z", "location_count": 41, "location_summary": "Chandler, Arizona • Los Angeles, California • Monterey, California + 34 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Monterey", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Whittier", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03523585" }, { "nct_id": "NCT00699998", "title": "A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Coronary Syndrome" ], "interventions": [ { "name": "Clopidogrel", "type": "DRUG" }, { "name": "Prasugrel", "type": "DRUG" }, { "name": "Commercially-available Aspirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9326, "start_date": "2008-06", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2013-05-07", "last_synced_at": "2026-10-09T18:22:38.058Z", "location_count": 165, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 162 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00699998" }, { "nct_id": "NCT06074705", "title": "A Study of DS-1471a In Subjects With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "DS-1471a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2023-08-04", "completion_date": "2025-07-29", "has_results": false, "last_update_posted_date": "2025-08-22", "last_synced_at": "2026-10-09T18:22:38.058Z", "location_count": 2, "location_summary": "Sarasota, Florida • Milwaukee, Wisconsin", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT06074705" }, { "nct_id": "NCT01107925", "title": "Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight With Coronary Artery Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Coronary Artery Disease" ], "interventions": [ { "name": "prasugrel", "type": "DRUG" }, { "name": "clopidogrel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "18 Years to 74 Years" }, "enrollment_count": 72, "start_date": "2010-03", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2012-08-30", "last_synced_at": "2026-10-09T18:22:38.058Z", "location_count": 2, "location_summary": "Jacksonville, Florida • Cincinnati, Ohio", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01107925" }, { "nct_id": "NCT06989112", "title": "DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometrial Cancer" ], "interventions": [ { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 600, "start_date": "2025-03-27", "completion_date": "2031-02-19", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-10-09T18:22:38.058Z", "location_count": 61, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Duarte, California + 55 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06989112" } ] }